Latest news with #VectorYTherapeutics
Associated Press
27-05-2025
- Business
- Associated Press
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
AMSTERDAM & BOSTON--(BUSINESS WIRE)--May 27, 2025-- VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships. This press release features multimedia. View the full release here: Jessica Atkinson, New CBO at VectorY Therapeutics Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors. 'I'm delighted to welcome Jessica to VectorY,' said Jim Scibetta, chief executive officer of VectorY Therapeutics. 'Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team.' 'VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases,' said Atkinson. 'I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success.' Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient. About VectorY VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see View source version on CONTACT: VectorY Therapeutics B.V. E-mail:[email protected] Tel: +31 20 226 8020 Vigo Consulting (Media) Melanie Toyne-Sewell / Rozi Morris E-mail:[email protected] Tel: +44 207 390 0237 / +44 20 7390 0231 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA INDUSTRY KEYWORD: SCIENCE NEUROLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: VectorY Therapeutics Copyright Business Wire 2025. PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
Yahoo
27-05-2025
- Business
- Yahoo
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
~ Veteran biotech executive to focus on long-term strategy and strategic partnerships to support VectorY's growth and pipeline advancement ~ AMSTERDAM & BOSTON, May 27, 2025--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships. Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors. "I'm delighted to welcome Jessica to VectorY," said Jim Scibetta, chief executive officer of VectorY Therapeutics. "Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team." "VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases," said Atkinson. "I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success." Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient. About VectorY VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see View source version on Contacts VectorY Therapeutics B.V.E-mail: info@ Tel: +31 20 226 8020Vigo Consulting (Media)Melanie Toyne-Sewell / Rozi MorrisE-mail: VectorY@ +44 207 390 0237 / +44 20 7390 0231 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Health
- Yahoo
VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
~ New data show AAV-delivered antibody fragments targeting oxidized phosphatidylcholines (PC-OxPL), a species of oxidized phospholipids, thereby neutralizing TDP-43 pathology and motor neuron toxicity in ALS models ~ ~ Underscores potential of VTx-001 to act on upstream drivers of ALS ~ AMSTERDAM & BOSTON, May 07, 2025--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the presentation of new preclinical data on one of its two therapeutic vectorized antibodies for ALS, VTx-001, at the Target ALS Annual Meeting in Boston, Massachusetts taking place between May 6-8, 2025. The data underscore the potential of VTx-001 to neutralize upstream pathological drivers in amyotrophic lateral sclerosis (ALS), including oxidized phosphatidylcholines (PC-OxPL), which have been implicated in triggering ALS hallmark TDP-43 proteinopathy and motor neuron degeneration. This research lays the foundation for a potential new therapeutic modality targeting oxidative phospholipid toxicity in ALS and possibly other neurodegenerative indications. VectorY's research team identified a distinct PC-OxPL profile in the brains of sporadic ALS (sALS) patients, with apolipoprotein E (APOE) particles emerging as the primary carriers of PC-OxPLs in the central nervous system. PC-OxPL exposure of iPSC-derived motor neurons induced an ALS-like transcriptome, significant TDP-43 pathology, and motor neuron death. In VectorY's preclinical data presented at the conference, VTx-001, an AAV-delivered, single-chain antibody fragment was shown to: Neutralize PC-OxPL-induced TDP-43 pathology Normalize disease-associated transcriptomic profiles Prevent motor neuron death and functional decline in vivo Achieve robust biodistribution and expression at therapeutic levels in a minipig model following intrathecal administration "These findings support our hypothesis that PC-OxPL molecules are a key mediator of ALS pathology, acting upstream of TDP-43 proteinopathy and motor neuron toxicity," said Sander van Deventer, M.D., Ph.D., president of research and development at VectorY Therapeutics. "VTx-001 offers a novel and complementary mechanism of action - to our lead candidate, VTx-002, which directly targets TDP-43 and for which we anticipate filing an IND before the end of this year." These data featured at the Target ALS Annual Meeting were recently published in the on-line publication bioRxiv. The manuscript, AAV-Delivered Anti-PC-OxPL Antibody Fragments: A Novel Therapeutic Approach to Target ALS, is available through the following link:
Business Wire
07-05-2025
- Health
- Business Wire
VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the presentation of new preclinical data on one of its two therapeutic vectorized antibodies for ALS, VTx-001, at the Target ALS Annual Meeting in Boston, Massachusetts taking place between May 6-8, 2025. 'These findings support our hypothesis that PC-OxPL molecules are a key mediator of ALS pathology, acting upstream of TDP-43 proteinopathy and motor neuron toxicity,' said Sander van Deventer, M.D., Ph.D., president of research and development at VectorY. Share The data underscore the potential of VTx-001 to neutralize upstream pathological drivers in amyotrophic lateral sclerosis (ALS), including oxidized phosphatidylcholines (PC-OxPL), which have been implicated in triggering ALS hallmark TDP-43 proteinopathy and motor neuron degeneration. This research lays the foundation for a potential new therapeutic modality targeting oxidative phospholipid toxicity in ALS and possibly other neurodegenerative indications. VectorY's research team identified a distinct PC-OxPL profile in the brains of sporadic ALS (sALS) patients, with apolipoprotein E (APOE) particles emerging as the primary carriers of PC-OxPLs in the central nervous system. PC-OxPL exposure of iPSC-derived motor neurons induced an ALS-like transcriptome, significant TDP-43 pathology, and motor neuron death. In VectorY's preclinical data presented at the conference, VTx-001, an AAV-delivered, single-chain antibody fragment was shown to: Neutralize PC-OxPL-induced TDP-43 pathology Normalize disease-associated transcriptomic profiles Prevent motor neuron death and functional decline in vivo Achieve robust biodistribution and expression at therapeutic levels in a minipig model following intrathecal administration 'These findings support our hypothesis that PC-OxPL molecules are a key mediator of ALS pathology, acting upstream of TDP-43 proteinopathy and motor neuron toxicity,' said Sander van Deventer, M.D., Ph.D., president of research and development at VectorY Therapeutics. 'VTx-001 offers a novel and complementary mechanism of action - to our lead candidate, VTx-002, which directly targets TDP-43 and for which we anticipate filing an IND before the end of this year.' These data featured at the Target ALS Annual Meeting were recently published in the on-line publication bioR x iv. The manuscript, AAV-Delivered Anti-PC-OxPL Antibody Fragments: A Novel Therapeutic Approach to Target ALS, is available through the following link: About ALS Amyotrophic lateral sclerosis (ALS), a motor neuron disease (MND) also known as Lou Gehrig disease, is a rare neurodegenerative disease characterized by the rapid and progressive loss of motor neurons, leading to paralysis, and death due to the inability to breathe. The vast majority of cases of ALS (90-95%) are categorized as sporadic, meaning they occur without a known cause, while 5-10% are familial, linked to a genetic mutation passed down through families. ALS is a fatal disease, with most individuals dying from complications such as respiratory failure within 3 to 5 years of diagnosis, though some may survive longer. About VectorY VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS. For more information, see
